title: Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor.
abstract: Factor VII (F.VII) is a vitamin-K-dependent serine protease required in the early stages of blood coagulation. We describe here a patient with severe F.VII deficiency, with a normal plasma F.VII antigen level (452 ng/mL) and F.VII activity less than 1%, who is homozygous for two defects: a G-->A transition at nucleotide 6055 in exon 4, which results in an Arg-->Gln change at amino acid 79 (R79Q); and a G-->A transition at nucleotide 8961 in exon 6, which results in an Arg-->Gln substitution at amino acid 152 (R152Q). The R79Q mutation occurs in the first epidermal growth factor (EGF)-like domain, which has previously been implicated in binding to tissue factor. The R152Q mutation occurs at a site (Arg 152-Ile 153) that is normally cleaved to generate activated F.VII (F.VIIa). Analysis of purified F.VII from patient plasma shows that the material cannot be activated by F.Xa and cofactors. In addition, in an in vitro binding assay using relipidated recombinant tissue factor, patient plasma showed markedly reduced binding to tissue factor at all concentrations tested. In an effort to separate the contributions of the two mutations, three recombinant variants, wild-type, R79Q, and R152Q, were prepared and analyzed. The R152Q variant had markedly reduced activity in a clotting assay, whereas R79Q showed a milder, concentration-dependent reduction. The R152Q variant exhibited nearly normal binding in the tissue factor binding assay, whereas the R79Q variant had markedly reduced binding. The time course of activation of the R79Q variant was slowed compared with wild-type. Our results suggest that the first EGF-like domain is required for binding to tissue factor and that the F.VII zymogen lacks activity and requires activation for expression of biologic activity.
authors.affiliation: Department of Medicine, University of North Carolina at Chapel Hill.
authors.forename: S
authors.initials: S
authors.lastname: Chaing
authors.forename: B
authors.initials: B
authors.lastname: Clarke
authors.forename: S
authors.initials: S
authors.lastname: Sridhara
authors.forename: K
authors.initials: K
authors.lastname: Chu
authors.forename: P
authors.initials: P
authors.lastname: Friedman
authors.forename: W
authors.initials: W
authors.lastname: VanDusen
authors.forename: H R
authors.initials: HR
authors.lastname: Roberts
authors.forename: M
authors.initials: M
authors.lastname: Blajchman
authors.forename: D M
authors.initials: DM
authors.lastname: Monroe
authors.forename: K A
authors.initials: KA
authors.lastname: High
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D001483:Base Sequence; D005167:Factor VII / Q000378:metabolism*; D005168:Factor VII Deficiency / Q000235:genetics*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D011994:Recombinant Proteins / Q000378:metabolism; D013925:Thromboplastin / Q000378:metabolism*
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; D013925:Thromboplastin